Literature DB >> 8328775

Constitutively vancomycin-resistant Enterococcus faecium resistant to synergistic beta-lactam combinations.

M Green1, B Binczewski, A W Pasculle, M Edmund, K Barbadora, S Kusne, D M Shlaes.   

Abstract

Vancomycin resistance among enterococci has recently been recognized. Synergy between vancomycin and penicillin has been shown in vitro for isolates of Enterococcus faecium resistant to both of these antibiotics. We describe three isolates of vancomycin-resistant E. faecium which demonstrate unique phenotypic characteristics. The isolates exhibited high-level resistance to both vancomycin and teicoplanin, consistent with the VanA phenotype. However, resistance in these isolates could not be induced or cured, and mating experiments failed to detect a transfer of resistance. The combination of vancomycin and penicillin did not significantly change the MIC of penicillin for any of the three isolates. Immunoblotting with polyclonal anti-VanB antibody showed no reaction with the cellular proteins of these strains. Probing with a vanA oligonucleotide revealed hybridization with chromosomal but not plasmid DNA. The mechanism of constitutive resistance of those strains remains unclear. A second mutational change, perhaps involving PBP 5, may explain the presence of resistance to synergistic combination penicillin-vancomycin therapy. In vitro evaluation of penicillin-vancomycin should be carried out in all clinical cases where this therapeutic regimen is being considered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328775      PMCID: PMC187946          DOI: 10.1128/AAC.37.6.1238

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Elimination of plasmids from several bacterial species by novobiocin.

Authors:  G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

2.  One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin.

Authors:  R Williamson; C le Bouguénec; L Gutmann; T Horaud
Journal:  J Gen Microbiol       Date:  1985-08

3.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

4.  Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.

Authors:  R Leclercq; E Derlot; J Duval; P Courvalin
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

5.  Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin.

Authors:  D M Shlaes; L Etter; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Transfer functions of the Streptococcus faecalis plasmid pAD1: organization of plasmid DNA encoding response to sex pheromone.

Authors:  E E Ehrenfeld; D B Clewell
Journal:  J Bacteriol       Date:  1987-08       Impact factor: 3.490

7.  Conjugative plasmid transfer from Enterococcus faecalis to Escherichia coli.

Authors:  P Trieu-Cuot; C Carlier; P Courvalin
Journal:  J Bacteriol       Date:  1988-09       Impact factor: 3.490

8.  Infection caused by vancomycin-resistant Streptococcus sanguis II.

Authors:  D M Shlaes; J Marino; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  Clinical laboratory challenges in the recognition of Leuconostoc spp.

Authors:  H D Isenberg; E M Vellozzi; J Shapiro; L G Rubin
Journal:  J Clin Microbiol       Date:  1988-03       Impact factor: 5.948

10.  Vancomycin-resistant streptococci or Leuconostoc sp.

Authors:  A Buu-Hoï; C Branger; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

View more
  9 in total

Review 1.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

2.  Resistant enterococci--mechanisms, laboratory detection and control in hospitals.

Authors:  J J Wade; A H Uttley
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

3.  Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium.

Authors:  S Handwerger; J Skoble
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

4.  Rapid detection of vancomycin-resistant enterococci.

Authors:  S C Edberg; C J Hardalo; C Kontnick; S Campbell
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

5.  Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium.

Authors:  W Zorzi; X Y Zhou; O Dardenne; J Lamotte; D Raze; J Pierre; L Gutmann; J Coyette
Journal:  J Bacteriol       Date:  1996-08       Impact factor: 3.490

6.  Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium.

Authors:  L Gutmann; S al-Obeid; D Billot-Klein; M L Guerrier; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Genetic basis for vancomycin-enhanced cephalosporin susceptibility in vancomycin-resistant enterococci revealed using counterselection with dominant-negative thymidylate synthase.

Authors:  Christopher J Kristich; Dusanka Djorić; Jaime L Little
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Simple test of synergy between ampicillin and vancomycin for resistant strains of Enterococcus faecium.

Authors:  M Green; K Barbadora; R M Wadowsky
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

Review 9.  Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen.

Authors:  R V Spera; B F Farber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.